NCT05524168View on ClinicalTrials.gov

SBRT Combined With PD-1 Antibody and Chemotherapy in Oligometastatic Nasopharyngeal Carcinoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

November 25, 2022

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2026

Conditions
Nasopharyngeal Carcinoma
Interventions
RADIATION

SBRT

SBRT for metastatic lesions

DRUG

Camrelizumab

Maximum 6 cycles for combined therapy. Camrelizumab maintenance for 1 year.

DRUG

Gemcitabine

Maximum 6 cycles for combined therapy.

DRUG

Cisplatin

Maximum 6 cycles for combined therapy.

Trial Locations (1)

510060

RECRUITING

Sun Yat-sen University Cancer Center, Guangzhou

All Listed Sponsors
collaborator

Shenzhen People's Hospital

OTHER

collaborator

First People's Hospital of Foshan

OTHER

collaborator

Jiangxi Provincial Cancer Hospital

OTHER

collaborator

The First Affiliated Hospital of Xiamen University

OTHER

collaborator

Chongqing University Cancer Hospital

OTHER

lead

Sun Yat-sen University

OTHER